These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 12474482)

  • 21. Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome.
    Ritmeijer K; Veeken H; Melaku Y; Leal G; Amsalu R; Seaman J; Davidson RN
    Trans R Soc Trop Med Hyg; 2001; 95(6):668-72. PubMed ID: 11816442
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Atypical disseminated leishmaniasis resembling post-kala-azar dermal leishmaniasis in an HIV-infected patient.
    Boumis E; Chinello P; Della Rocca C; Paglia MG; Proietti MF; Petrosillo N
    Int J STD AIDS; 2006 May; 17(5):351-3. PubMed ID: 16643688
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B in patients infected with human immunodeficiency virus.
    Torre-Cisneros J; Villanueva JL; Kindelan JM; Jurado R; Sanchez-Guijo P
    Clin Infect Dis; 1993 Oct; 17(4):625-7. PubMed ID: 8268341
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Visceral leishmaniasis in patient with HIV infection].
    Olea P; Pinilla J
    Rev Chilena Infectol; 2013 Apr; 30(2):216-20. PubMed ID: 23677161
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The first case of visceral leishmaniasis in a patient with HIV infection in Russia].
    Ermak TN; Kravchenko AV; Gruzdev BM; Filippov PG
    Ter Arkh; 1997; 69(11):48-50. PubMed ID: 9483748
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pentamidine as secondary prophylaxis for visceral leishmaniasis in the immunocompromised host: report of four cases.
    Patel TA; Lockwood DN
    Trop Med Int Health; 2009 Sep; 14(9):1064-70. PubMed ID: 19552658
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Miltefosine for visceral leishmaniasis.
    Sherwood JA
    N Engl J Med; 2000 Mar; 342(12):895. PubMed ID: 10733377
    [No Abstract]   [Full Text] [Related]  

  • 28. [Leishmaniasis. Basic principles, clinical aspects, diagnosis and therapy].
    Burbach G; May J; Harms G; Bienzle U
    Dtsch Med Wochenschr; 1999 Jan; 124(4):88-93. PubMed ID: 10071606
    [No Abstract]   [Full Text] [Related]  

  • 29. In-vitro and in-vivo studies on a topical formulation of sitamaquine dihydrochloride for cutaneous leishmaniasis.
    Garnier T; Brown MB; Lawrence MJ; Croft SL
    J Pharm Pharmacol; 2006 Aug; 58(8):1043-54. PubMed ID: 16872550
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Nephrotic syndrome and acute pancreatitis related to glucantime administration].
    Valencia ME; Laguna F; González Lahoz J
    An Med Interna; 2000 Jan; 17(1):54. PubMed ID: 10730416
    [No Abstract]   [Full Text] [Related]  

  • 31. Clinical aspects of visceral leishmaniasis in HIV infection.
    Jarvis JN; Lockwood DN
    Curr Opin Infect Dis; 2013 Feb; 26(1):1-9. PubMed ID: 23221770
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long term failure of miltefosine in the treatment of refractory visceral leishmaniasis in AIDS patients.
    Troya J; Casquero A; Refoyo E; Fernández-Guerrero ML; Górgolas M
    Scand J Infect Dis; 2008; 40(1):78-80. PubMed ID: 17852921
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The irreplaceable image: Acute toxicity in erythroid bone marrow progenitors after antimonial therapy.
    Hernández JA; Navarro JT; Force L
    Haematologica; 2001 Dec; 86(12):1319. PubMed ID: 11726328
    [No Abstract]   [Full Text] [Related]  

  • 34. Miltefosine in a case of visceral leishmaniasis with HIV co-infection; and rising incidence of this disease in India.
    Thakur CP; Sinha PK; Singh RK; Hassan SM; Narain S
    Trans R Soc Trop Med Hyg; 2000; 94(6):696-7. PubMed ID: 11198660
    [No Abstract]   [Full Text] [Related]  

  • 35. Phase 2 efficacy trial of an oral 8-aminoquinoline (WR6026) for treatment of visceral leishmaniasis.
    Sherwood JA; Gachihi GS; Muigai RK; Skillman DR; Mugo M; Rashid JR; Wasunna KM; Were JB; Kasili SK; Mbugua JM
    Clin Infect Dis; 1994 Dec; 19(6):1034-9. PubMed ID: 7888530
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Acute pancreatitis due to antimonials in patients with visceral leishmaniasis and HIV infection].
    Cortés E; Ribera E; Cucurull E; de Otero J; Ocaña I; Pahissa A
    Med Clin (Barc); 1995 Apr; 104(15):578-80. PubMed ID: 7769868
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Post-Kala-Azar dermal leishmaniasis in an HIV-1-infected woman: recovery after amphotericin B following failure of oral miltefosine.
    Guffanti M; Gaiera G; Bossolasco S; Ceserani N; Ratti D; Cinque P; Salmaso F; Gianotti N; Lazzarin A
    Am J Trop Med Hyg; 2008 Nov; 79(5):715-8. PubMed ID: 18981510
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interaction of sitamaquine with membrane lipids of Leishmania donovani promastigotes.
    Dueñas-Romero AM; Loiseau PM; Saint-Pierre-Chazalet M
    Biochim Biophys Acta; 2007 Feb; 1768(2):246-52. PubMed ID: 16945323
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ketoconazole in the treatment of visceral leishmaniasis (kala-azar).
    Ahasan HA; Rafiqueuddin AK; Azhar MA; Chowdhury MA
    Trop Doct; 1996 Oct; 26(4):197-8. PubMed ID: 8937249
    [No Abstract]   [Full Text] [Related]  

  • 40. [Treatment of visceral leishmaniasis: recent modalities].
    Gangneux JP
    Presse Med; 1999 Nov; 28(37):2057-66. PubMed ID: 10605480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.